top of page
Search
Sep 15, 2021
Coave Therapeutics and Théa Open Innovation sign exclusive agreement
Coave Therapeutics enters into an exclusive licensing, co-development, and commercialization agreement with Théa Pharma.
Aug 11, 2020
FDA grants fourth ODD for treatment of PDE6B gene mutation-associated retinal diseases
FDA granted 4th Orphan Drug Designation for novel gene therapy product candidate (OCU400, Ocugen Inc.) in treatment of PDE6B gene mutation.
Jun 30, 2018
ARL2BP, a protein linked to retinitis pigmentosa, is needed for normal photoreceptor cilia doublets and outer segment structure
The current study focused on the cilia-specific role for ARL2BP in photoreceptor cells.
Apr 17, 2018
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients with Rod-Cone Dystrophy associated
Compares genotype, phenotype, and structural changes in patients with rod-cone dystrophy (RCD) associated with mutations in PDE6A or PDE6B
Oct 14, 2016
Prenylated retinal ciliopathy protein RPGR interacts with PDE6B,
Regulates ciliary localization of Joubert syndrome-associated protein INPP5E Kollu N. Rao, Wei Zhang, Linjing Li, Manisha Anand, and...
Oct 14, 2016
Prenylated retinal ciliopathy protein RPGR interacts with PDE6B and regulates ciliary localization of Joubert syndrome-associated protein INPP5E
RPGR as a critical to cilia and suggest that trafficking of INPP5E to cilia depends upon the interaction of RPGR with PDE6B.
Aug 13, 2013
Therapeutic Margins in a Novel Preclinical Model of Retinitis Pigmentosa
The third-most common cause of autosomal recessive retinitis pigmentosa (RP) is due to defective cGMP phosphodiesterase-6 (PDE6).
Jan 1, 1996
A Homozygous PDE6B Mutation in a Family with Autosomal Recessive Retinitis Pigmentosa
With a similar approach, homozygous mutations also have been found in PDE6B in the affecteds of two other ARRP families.
All Posts
bottom of page